Key clinical point: While adjuvant axitinib failed to improve disease-free survival in a recent phase 3 renal cell carcinoma trial, the highest-risk subgroup appeared to benefit.
Major finding: The highest-risk subpopulation (pT3 with Fuhrman grade greater than or equal to 3 or pT4 and/or N+, any T, any Fuhrman grade) had a reduction of risk per assessments by independent review committee (HR, 0.735; P = .0704) and investigators (HR, 0.641; P = .0051).
Study details: Results from ATLAS, a phase 3, randomized trial including 724 patients with locoregional RCC.
Disclosures: The study was sponsored by Pfizer and SFJ Pharmaceuticals. Study authors reported disclosures related to Pfizer, Bayer, Novartis, Bristol-Myers Squibb, Merck, Exelixis, Genentech, Roche, AstraZeneca, and Astellas, among others.
Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454